News
06-07-2010, 07:22 AM
Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB) through LRP-1 targeting, announced today that complete phase 1/2 clinical data in two clinical studies of its lead oncology program, ANG1005, for the treatment of brain cancers, including glioblastoma (GBM) and brain metastases, were presented at the 2010 American Society for Clinical Oncology (ASCO) Annual Meeting, June 4-8, in Chicago, IL.
More... (http://www.news-medical.net/news/20100607/Angiochem-presents-positive-Phase-12-clinical-data-of-ANG1005-for-brain-cancer-at-ASCO-2010.aspx)
More... (http://www.news-medical.net/news/20100607/Angiochem-presents-positive-Phase-12-clinical-data-of-ANG1005-for-brain-cancer-at-ASCO-2010.aspx)